Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|January 27, 2020
PPD Launches IPO
Author(s)Pharmaceutical Technology Editors
Drug development contract services company PPD announces initial public offering.
Advertisement
On Jan. 27. 2020, contract service provider PPD, Inc. announced the launch of an initial public offering (IPO), potentially worth $1.6 billion; the company said it intends to use the net proceeds from the IPO to cover debt and for general corporate purposes.
In a press statement, the company said it plans to issue 60 million shares of its common stock with the initial stock price expected to be between $24–$27 per share, the company reported.
The company has applied with the Securities and Exchange Commission to have its common stock approved for listing on The Nasdaq Global Select Market under the symbol “PPD.”
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement